Recherche avancée

Karl-Ludwig Kley est un homme d'affaires allemand qui a été à la tête de 7 entreprises différentes. Il occupe le poste de président du conseil de surveillance de E.ON SE, de président du conseil de surveillance de Deutsche Lufthansa AG et de codirecteur de Glasbau Hahn GmbH. M. Kley est également membre du conseil d'administration de Bayerische Motoren Werke AG, de Fritz Thyssen Stiftung et de Deutsche Akademie der Technikwissenschaften eV, ainsi que président du conseil d'administration de Baden Badener Unternehmergesprche, vice-président de Bundesverband der Deutschen Industrie e.V., membre du conseil exécutif de E. Merck KG et vice-président de Verband der Chemischen Industrie eV.
Au cours de sa carrière, M. Kley a été président du conseil d'administration de Merck KGaA, directeur des finances et des relations avec les investisseurs de Bayer AG et directeur financier de Bayer Holding Ltd. (une filiale de Bayer AG), président du conseil de surveillance de Lufthansa AirPlus Servicekarten GmbH, président du conseil de surveillance de 1. FC Kln GmbH & Co. KGaA, directeur du conseil d'administration de KG Allgemeine Leasing GmbH & Co. et chef de la division pharmaceutique de Bayer SpA.
Le Dr Kley a obtenu un doctorat, un diplôme d'études supérieures et un diplôme d'études supérieures de la Ludwig-Maximilians-Universitt Mnchen.

Karl-Ludwig Kamprath formerly worked at Deutsche Sparkassen Leasing AG & Co. KG, as Chairman-Supervisory Board, Kreissparkasse München Starnberg Ebersberg, as Chairman, Deutsche Leasing AG, as Chairman-Supervisory Board, LfA Förderbank Bayern, as Director-Management Board, BayernLB Holding AG, as Director, GTU Geothermie Unterschleißheim AG, as Director-Supervisory Board from 2010 to 2012, and Baader Bank AG, as Member-Supervisory Board from 2010 to 2018.

Nikolai Kley is the founder of two companies, FORMA Therapeutics, Inc. (founded in 2008) and Orionis Biosciences, Inc. (founded in 2015).
At FORMA Therapeutics, he held the title of VP-Biology & Head-Drug Discovery Research from 2008 to 2011.
At Orionis Biosciences, he held the titles of President, Chief Executive Officer & Director from 2015 to present, and currently holds the titles of Managing Director & Director at Orionis Biosciences BV since 2015 and Professor at Princeton University.
He previously worked at Bristol Myers Squibb Co. as a Principal, GPC Biotech AG as a Vice President, The General Hospital Corp.
as a Fellow, Genome Therapeutics Corp.
as a Vice President, and Harvard Medical School as a Fellow.
He received his undergraduate degree from the University of Leeds and doctorate degrees from Max-Planck-Institute for Molecular Genetics and Ludwig-Maximilians-Universität München.

Mr. Jason B.
Kley is Senior Integrated Wealth Advisor at Carlson Capital Management, Inc. He is a member of the Minnesota Financial Planning Association.
Before joining the CCM, Mr. Kley worked for a Minneapolis wealth management firm where he served as a financial advisor, investment committee member, and 401k plan specialist.
Prior to that, he worked for Thrivent Financial and Union Pacific, serving in business analyst and strategic operational roles.
Mr. Kley has also served on the Minneapolis Regional Chamber of Commerce DRIVE Emerging Leaders Board, Best Prep’s Minnesota Business Venture Advisory Committee, and the City of St. Louis Park Police Advisory Commission.
He holds a Bachelor of Arts degree in Math and Computer Science from the University of St. Thomas where he graduated magna cum laude in 1998.
He also earned an MBA with an emphasis in Finance and Strategy from Washington University in St. Louis, Missouri.

Karl-Ludwig Diehl is currently a Managing Director-Germany at Woodbridge International LLC.
He obtained an undergraduate degree from Friedrich-Alexander University of Erlangen-Nuremberg.